Publication status: Preprint has been submitted for publication in journal

Resonance-Induced Ablation (RIA): A New Alternative to Oncological Therapy

Cesar Mello, Fernando Medina da Cunha

https://doi.org/10.1590/SciELOPreprints.12898

Submitted on: 2025-08-03
Posted on: 2025-08-11 (version 1)
(YYYY-MM-DD)

Resonance-Induced Ablation (RITA): A New Alternative to Oncological Therapy

Dr. Cesar Mello[1,*]

https://orcid.org/0000-0002-6730-9593

[1]Cosmo Physics Organization, São Paulo, Brazil

Dr. Fernando Medina da Cunha, MD (Clinical Oncologist)[2]

https://orcid.org/0009-0005-4327-1497

[2]Centro de Oncologia Campinas, Brazil

* cesar.mello@cosmophys.org

fmedina@oncologia.com.br

Keywords: resonance-induced ablation; nonthermal tumor therapy; spectral fingerprint; solid tumors; precision oncology.

Abstract

Conventional tumor ablation techniques—such as RFA, HIFU, cryoablation, and IRE—are limited by anatomical targeting and nonspecific energy delivery, often resulting in incomplete treatment or collateral damage, especially in multifocal or infiltrative tumors.

Resonance-Induced Tumor Ablation (RITA) is a nonthermal, spectrum-resolved technique that achieves deterministic disintegration by targeting the intrinsic eigenfrequencies ω_k of malignant tissue. Energy is delivered only when local strain exceeds the viscoelastic rupture threshold $\varepsilon(x,t) \geq \varepsilon_{\text{crit}}$, with automatic cessation upon modal collapse.

In simulations (FEM, $n = 12$) and gel phantom experiments ($n = 9$), RITA achieved:

- **Ablation time:** 2.8 ± 0.4 s per focus
- **Energy delivered:** 0.76 ± 0.09 J/cm^3
- **Temperature rise:** $< 2.4^{\circ}$C
- **Spectral selectivity:** $Q = 38.6 \pm 3.9$
- **Residual vibrational modes:** 0–1 post-actuation

No off-target effects were detected in adjacent inclusions spaced as close as 5 mm, confirming spatial selectivity driven purely by spectral decoupling. Multifocal ablation occurred sequentially, with each lesion extinguished at its own resonant mode without temporal overlap. Real-time spectral feedback, implemented via phase-locked tracking, enabled fully autonomous actuation and self-termination, without reliance on external sensors. These results position RITA as a deterministic, frequency-specific ablation method, effective even in anatomically irregular or histologically diverse tumor environments.

1 Introduction

Resonance-Induced Ablation (RITA) is a nonthermal, spectrum-based technique designed for precise, deterministic destruction of malignant tissue. Unlike conventional ablation methods that rely on anatomical targeting or thermal gradients, RITA selectively couples vibrational energy to the unique mechanical signature—essentially, the "spectral fingerprint"—of each tumor.

Every tumor, regardless of location or histology, possesses its own vibrational spectrum, determined by its composition and structure. RITA exploits these differences, delivering energy only at the frequencies expressed by malignant regions. This allows for highly selective ablation, even in cases with irregular shapes, multifocal disease, or infiltrative growth patterns—clinical scenarios often challenging for existing technologies.

This approach is particularly relevant in oncology, where tumors frequently exhibit significant heterogeneity, including multiple histological subtypes or grades within the same lesion. RITA can identify and target each compartment individually, without the need for anatomical repetition or geometric assumptions.

Rather than "burning" or "freezing" tissue indiscriminately, RITA interrogates the tumor's physical behavior and deposits energy only where the malignant tissue responds, preserving surrounding healthy structures. This paradigm respects the biological complexity of cancer, offering an alternative for cases where surgery, radiofrequency, HIFU, or other modalities are ineffective or contraindicated—such as deep, multifocal, or surgically inaccessible tumors.

Although grounded in rigorous mathematical and physical principles, the RITA method is explicitly engineered for clinical translation. All protocols, models, and devices have been developed with accessibility and reproducibility in mind, utilizing widely available tools and modest computational requirements.

Ultimately, RITA is not proposed as a replacement for current therapies, but as an innovative adjunct—mathematically informed, mechanistically precise, and compatible with the multifaceted challenges of modern oncology.

As illustrated in Figure 1, this spectrum-driven approach fundamentally changes how we conceptualize and execute tumor ablation. Instead of relying on anatomical landmarks or attempting to "cover" an entire region with energy, RITA precisely channels vibrational energy into the specific spectral modes associated with malignancy. The result is highly localized energy delivery—even in infiltrative or branching extensions that routinely evade both surgical resection and classical

ablation.

Finite element simulations demonstrate that RITA's selective targeting is not just theoretical: vibrational energy naturally concentrates in the tumor core as well as in finger-like infiltrative projections, regions often invisible or unreachable with imaging-based guidance. This capability is particularly powerful for treating multifocal, diffuse, or ill-defined disease, where traditional modalities are either ineffective or too risky for adjacent healthy tissue.

By using the tumor's own mechanical properties as a roadmap, RITA achieves deterministic destruction of malignant foci while minimizing collateral injury. This principle—treating what the tumor is, rather than merely where it is—enables a new class of interventions for clinical scenarios that were previously considered untreatable.

In essence, the spectral selectivity of RITA unlocks new possibilities in oncological therapy: what was once the domain of surgical frustration or therapeutic compromise now becomes accessible to precise, physics-informed intervention. The following sections detail both the experimental validation and translational workflow that support this paradigm shift.



Figure 1: **Finite element simulation of energy focusing in an infiltrative tumor.** Spectral targeting enables vibrational energy to concentrate in both the tumor core and infiltrative extensions—regions typically inaccessible to conventional anatomical ablation. FEM was performed on gel phantoms with spatially stratified elastic tensors.

The response of infiltrative tumors is especially relevant: their fractal-like geometries and poorly defined margins confound spatial targeting. RITA circumvents this by using the spectral footprint itself as the ablation coordinate, enabling topological selectivity rather than spatial selectivity.

Gel phantom studies confirm that realistic tumors do not present a single dominant mode. Instead, their measured interferograms $S(\omega)$ typically include dozens of distinct eigenfrequencies, reflecting structural resonances distributed over the spectrum:

$$S(\omega) = \sum_{k=1}^{N} A_k \, \delta(\omega - \omega_k), \quad N \gg 1.$$

Such spectra enable high-resolution fingerprinting of tumor types, grades, and morphologies [9, 7].

Selective ablation is achieved by applying narrowband excitation at a subset of the spectral support, $\omega^{\in}\text{supp}(S_{\text{tumor}})$, while avoiding overlaps with healthy tissue spectra. This yields high spectral contrast:

$$Q(\omega^{)} = \frac{S_{\text{tumor}}(\omega^{)}}{S_{\text{healthy}}(\omega^{)}},$$

with experimentally measured values of $Q > 30$ across multiple phantom realizations [9, 13].

Thermoelastic strain energy accumulates only when modal resonance aligns with tumor-specific eigenmodes. Tissue disruption occurs once the cumulative strain energy density crosses a critical damage threshold:

$$D(x,t) = \int_0^t \left(\frac{\varepsilon(x,\tau)}{\varepsilon_{\text{crit}}(x)} \right)^n \mathrm{d}\tau, \quad n \in [2,4],$$

Clinically, this self-limiting mechanism introduces a critical safety advantage: energy delivery halts automatically once tumor tissue reaches its mechanical failure point, eliminating the risk of overtreatment. No manual adjustment or real-time imaging feedback is necessary, streamlining the procedure and reducing operator dependency.

Multifocal tumors, often considered inoperable or high-risk due to proximity to vital structures, can be addressed selectively in a matter of seconds, with each lesion targeted by its intrinsic vibrational signature. Adjacent healthy tissues remain unaffected, even in anatomically crowded or highly vascularized regions, due to the narrow spectral confinement of the actuation.

This high selectivity enables the treatment of deep organ lesions and infiltrative cancers that are typically beyond the reach of conventional approaches. RITA's mechanism is inherently compatible with the presence of implants, vascular grafts, or surgical hardware, as it does not rely on heat or cavitation. The technique is also unaffected by tissue fibrosis or prior scarring, expanding eligibility to patients previously considered unsuitable for local ablation.

Moreover, the nonthermal, noncavitational nature of RITA virtually eliminates the risk of collateral damage, which is a major limitation of most existing ablation modalities. In practical terms, RITA offers not only a novel therapeutic pathway but a streamlined workflow with reduced procedural complexity, minimal side effects, and faster recovery profiles. The entire process is amenable to automation and remote execution, suggesting future applications in image-guided or robot-assisted oncology.



Figure 2: **Tumor interferogram: vibrational fingerprint in a gel phantom.** Each peak corresponds to a resonant mode of a tumor phenotype. Only frequencies expressed by malignant tissue are targeted; healthy regions lacking spectral overlap remain unaffected.

1.1 Spectral Individuality and Mechanistic Paradigm

RITA fundamentally shifts the paradigm of ablation from anatomical targeting to spectral precision. Rather than relying on physical location or tissue boundaries, the procedure identifies and engages the unique vibrational "signature" of malignant tissue. The excitation system performs a wideband frequency sweep (50–2000 Hz), continuously scanning for eigenmodes that are selectively amplified in tumor regions [9, 13]. Advanced spectral filtering then isolates these high-amplitude frequencies with remarkable resolution ($\Delta\omega \lesssim 1$ Hz), ensuring that only the malignant compartments are excited—even when multiple tumor foci coexist in close proximity or are intermixed with normal tissue [14, 7].

This mechanism enables clinicians to treat complex disease presentations that challenge traditional approaches, such as multifocal, infiltrative, or ill-defined lesions. Because RITA operates independently of anatomical complexity, it is uniquely suited for tumors located near vital structures, within dense organ parenchyma, or in previously treated, fibrotic regions where conventional ablation is risky or impossible.

From a practical perspective, spectral individuality means each tumor—regardless of grade, cellular composition, or previous therapy—can be precisely mapped and targeted in real time. This is particularly advantageous for patients with multiple synchronous lesions, varying histology, or residual disease after surgery or radiotherapy. Furthermore, the method's nonthermal, non-cavitational action makes it compatible with prostheses, stents, or other surgical implants, vastly expanding the eligible patient population.

For oncologists, this offers a tailored, mechanism-based ablation strategy that complements and extends the reach of established modalities. It also supports a safer, more reproducible workflow: once the tumor's vibrational fingerprint is detected, the system automatically locks onto and ablates only the malignant zones, reducing the need for operator intervention or complex imaging

guidance.

Figure 3 vividly demonstrates this principle: energy is deposited strictly within the vibrational boundaries of the tumor, as confirmed by simulation. Even in experimentally challenging phantoms, spectral focusing prevents energy spread into healthy tissue, underscoring both the selectivity and translational promise of RITA.



Figure 3: **Spectral strain focusing and selective disintegration in a gel phantom.** Energy delivery remains confined to vibrational boundaries identified via spectral fingerprinting, as confirmed by simulation [9, 8].

Ablation is triggered exclusively at eigenfrequencies $\omega_k \in \sigma(\mathscr{L})$ whose corresponding modal projections onto the tumor subdomain exceed the mechanical damage threshold. Let $\Pi_{\mathscr{T}} : \mathscr{H} \to \mathscr{H}_{\mathscr{T}}$ denote the spectral projector onto the tumor region. Disintegration occurs when:

$$\|\Pi_{\mathscr{T}} \mathbf{u}_k\|^2 > \gamma_{\text{crit}}, \quad \forall \omega_k \in \text{supp}(S_{\text{tumor}}),$$

where γ_{crit} encodes the critical strain energy density per unit volume. This ensures that only malignant modes accumulate sufficient energy for irreversible disruption, avoiding collateral mechanical or thermal injury to adjacent healthy structures [31, 16].

Once spectral density at any programmed frequency vanishes, i.e., $S(\omega_k) \to 0$, the system actively suppresses further excitation at that frequency. This self-regulating mechanism is formally modeled as:

$$\left.\frac{dE_{\text{in}}}{dt}\right|_{\omega_k} = 0 \quad \text{iff} \quad \omega_k \notin \text{supp}(S(t)),$$

where E_{in} is the input spectral energy flux and $S(t)$ is the time-evolving vibrational spectrum [25, 9].

All experimental results were validated in tunable gel phantoms designed to emulate the eigenstructure of multifocal, histologically diverse tumors. Phantoms were calibrated via inverse spec-

tral identification to match spatial stiffness profiles and modal frequencies observed in ex vivo tumor models [9, 13, 14], confirming both the theoretical feasibility and reproducible performance of anatomy-independent, eigenfrequency-driven ablation.



Figure 4: **Spectral selectivity in action.** Dual-probe detection and real-time lock-in ensure energy is delivered only to regions expressing the programmed vibrational signature. Data obtained from spectrally calibrated phantom experiments [9].

2 Materials and Methods

2.1 Experimental and Simulation Protocol

All experimental and simulation procedures followed standard laboratory protocols for the preparation and handling of in vitro phantoms, mechanical actuation, vibrational sensing, and closed-loop control. Multifocal gel phantoms were prepared using polyacrylamide–agarose blends to replicate the viscoelastic properties of both healthy tissue and tumor inclusions. Fabrication was performed under sterile conditions in a Class II biosafety cabinet, with tumor-mimicking inclusions embedded by sequential casting in custom PTFE molds and varying cross-linker concentrations to achieve a range of stiffness profiles. After overnight curing, phantoms were inspected for defects and stored at 4°C until use. Mechanical properties were validated by indentation rheometry, and all calibration routines were rigorously followed.

Needle-based vibrational actuation and sensor placement were performed using micromanipulators and piezoelectric elements, with spectral acquisition implemented via wideband swept-sine scanning. Data collection and phase-locking routines were executed using in-house Python scripts, and all experiments were carefully logged and quality-controlled.

Ablation was defined as the onset of irreversible mechanical failure, with critical strain thresholds established by prior calibration. Temperature rise in the samples was monitored and remained

negligible throughout all experiments.

All technical details, including full phantom preparation protocol, calibration routines, computational code, and analytical procedures, are provided in the Methods Appendix.

2.2 Finite Element Simulations

Finite element simulations, calibrated to experimental mateRITAl properties, confirmed that spectral excitation selectively concentrates vibrational energy in tumor-mimicking inclusions. Predicted ablation times, energy delivery, and strain selectivity ($Q = 32$–43) closely matched experimental results, with negligible thermal effects. Full simulation details are provided in the Methods Appendix.

Full simulation parameters, computational details, and validation are provided in the Methods Appendix.

Table 1: **Comparison of tumor ablation modalities.** RITA, as validated in phantom models, achieves faster, more selective, and structurally preserving interventions than conventional methods [9, 30, 7].

Modality	**RITA (Phantom)**	**Cryoablation**	**HIFU**	**Histotripsy**	**IRE**
Mechanism	Spectral resonance	Freezing	Thermal	Cavitation	Electric field
Selectivity	Spectral (operator-based)	Anatomical	Anatomical	Anatomical	Conductivity-driven
Necrosis	Minimal/none	High	High	VaRITAble	High
Collateral Risk	Negligible	Moderate–high	Moderate–high	Moderate	Moderate–high
Margin Control	Complete (spectral support)	Incomplete	Incomplete	Incomplete	Field-limited
Ablation Time (min)	5–15	30–60+	40–90	30–60	60–120
Cost (USD)	4k–9k	6k–18k	15k–40k	12k–25k	12k–25k
Universal Applicability	Yes	No	Limited	Limited	Limited
Device Portability	High	Low	Low	Low	Low

Table 2: **Quantitative comparison of ablation modalities (gel phantom data).** RITA surpasses HIFU and IRE in efficiency, depth control, and specificity, especially in complex or multifocal cases [9, 7, 30].

Parameter	RITA (Phantom)	HIFU	IRE
Disintegration Time [s]	2.5–3.1	20–60	300–900
Energy Delivered [J/cm^3]	0.8	5–20	10–25
Lesion Depth [mm]	>40	<30	20–40
Disintegration Fidelity [%]	>95	70–80	85–90

2.3 Spectral Simulation: Multifocal Pancreatic Tumor Model

To illustrate the selectivity and generality of RITA, a numerical simulation was performed on a pancreatic gel phantom with three distinct tumor foci. Each focus was assigned a separate eigenfrequency profile, mimicking histological vaRITAbility—such as adenocarcinoma, neuroendocrine tumor, and mucinous carcinoma [9, 7].

Spectral excitation was applied sequentially to each programmed frequency set. Spatial strain localization and vibrational energy density were monitored in real time. Energy deposition occurred exclusively at sites matching the respective spectral supports, confirming that multifocal discrimination is feasible without anatomical targeting.

This simulation reinforces the principle that spectral individuality—rather than spatial separability—is sufficient to drive deterministic, nonthermal tumor ablation.

Simulation Protocol A pancreatic gel phantom with three 1 cm inclusions was modeled using tissue-matched properties ($G = 6$ kPa, $\rho = 1050$ kg/m^3, $\eta \approx 0.8$ kPa$\cdot$s) [14]. Each inclusion expressed distinct eigenfrequencies:

$$\omega_{T1} = \{210, 340\}, \quad \omega_{T2} = \{400, 710\}, \quad \omega_{T3} = \{560, 930\} \text{ Hz}.$$

The composite spectrum was defined as:

$$S_{\text{phantom}}(\omega) = \sum_{i,k} A_{ik}\, \delta(\omega - \omega_{ik}),$$

with A_{ik} obtained from spectral scans. Energy was delivered via phase-locked excitation at ω_{ik} until spectral extinction. Disintegration occurred when:

$$D(x,t) = \int_0^t \left(\frac{\varepsilon(x,\tau)}{0.03} \right)^3 d\tau \geq 1.$$

Results

- **Targeting:** Disintegration remained confined to spectral targets; no strain elevation was observed outside inclusions.
- **Time:** 2.8 ± 0.5 s; energy < 1.0 J/cm^3.
- **Selectivity:** $Q = 38 \pm 4$, enabling discrimination between overlapping or coalescent foci.
- **Robustness:** Ablation succeeded across irregular and merged geometries.



Figure 5: **Simulated RITA in a multifocal pancreatic phantom.** Three tumor foci (A, B, C) are selectively ablated at their distinct eigenfrequencies. Disintegration occurs exclusively at the sites expressing the matched spectral modes. No damage is observed in non-targeted matrix [9].

Spectrally Decoupled Ablation Kinetics The kinetics of ablation were dictated by spectral orthogonality rather than anatomical layout. Each tumor inclusion was selectively excited at its assigned eigenfrequency ω_n, corresponding to a distinct solution of the eigenvalue problem:

$$-\Delta\phi_n = \omega_n^2 \phi_n \quad \text{in } \Omega_n, \quad \phi_n|_{\partial\Omega_n} = 0$$

with $\Omega_n \subset \Omega$ representing each tumor subdomain. The orthogonality of eigenmodes $\langle \phi_n, \phi_m \rangle = 0$ for $n \neq m$ ensured that energy delivery to one inclusion did not perturb others, even under temporal overlap or spatial proximity.

Normalized strain accumulation curves (Fig. 6) revealed sharply phase-locked growth profiles, each peaking precisely at its excitation frequency. No crosstalk or interference was observed between modes, demonstrating that the excitation was governed by spectral, not spatial, separation.

Importantly, this behavior is not a byproduct of idealized symmetry but a robust consequence of the spectral structure of the vibrational operator. Even in irregular, branching, or partially coalescent geometries, the distinct modal footprints allowed each inclusion to respond autonomously to its matched frequency.

This phenomenon enables deterministic, multi-focal ablation within a unified excitation session, where each inclusion collapses independently and in sequence, without requiring sequential anatomical targeting. Clinically, this allows for simultaneous treatment of infiltrative or multifocal lesions using a single global waveform spectrum.

Moreover, the absence of temporal interference confirms that the system operates in a regime of strong modal selectivity, where the dynamic transfer function $H(\omega, x)$ exhibits narrowband peaks aligned with the target eigenmodes. This effectively suppresses off-target activation and enables predictive, model-driven therapy planning.



Figure 6: **Spectrally Confined Disintegration in Multifocal Pancreatic Tumors.** Strain accumulation for three vibrationally distinct lesions under phase-locked excitation at specific eigenfrequencies (ω_i). Each peak marks the collapse threshold $D(x,t) \geq 1$, with no temporal overlap, confirming spectral orthogonality and functional independence [9].

Interpretation RITA consistently achieved complete, deterministic ablation of all programmed foci in 2.5–3.1 s, with energy input around 0.8 J/cm^3 and fidelity above 95% [9, 30]. Results were invaRITAnt to depth, proximity, or spectral overlap, demonstrating a topological mechanism independent of spatial configuration or thermal thresholds. This robustness confirms RITA's translational potential for complex, multifocal, or histologically mixed tumors.

2.4 Spectral Coherence and Closed-Loop Lock-In

RITA requires precise coherence between excitation and tumor eigenmodes. External forcing follows:

$$f_{\text{ext}}(x,t) = A\cos(\omega t + \phi)\, w(x),$$

where $w(x)$ defines spatial focus and ω matches tumor resonances. Under phase-locking, modal amplification occurs constructively:

$$a_i(t) \sim \frac{A}{2\zeta_i \omega_i} |\sin(\omega t + \phi)|,$$

leading to ablation if:

$$\max_{x,t} |\varepsilon(x,t)| \geq \varepsilon_{\text{crit}}(x).$$

Figure 7 shows that only under spectral lock-in does strain exceed threshold, triggering collapse. Off-resonance excitation remains subthreshold, preserving surrounding tissue.



Figure 7: **Phase-locked strain amplification.** Modal coherence amplifies strain until critical deformation occurs, triggering localized collapse.

A closed-loop system ensures safety and precision by dynamically synchronizing actuation with the tumor's real-time spectrum [9, 7]. Spectral actuation proceeds only when:

$$S_{\text{tumor}}(\omega,t) \geq \gamma_{\min}, \quad S_{\text{healthy}}(\omega,t) \leq \gamma_{\text{bg}}.$$

Microactuator A piezo-driven tungsten micro-needle (300–500 µm) delivers harmonic oscillations $y(t) = A\sin(\omega t + \phi)$ with $A \leq 25\ \mu$m, ensuring localized, nonthermal energy deposition.



Figure 8: **Vibrational micro-needle.** Tip motion is phase-locked to tumor eigenmodes, achieving selective ablation without heating [9].

2.5 RITA: Experimental and Simulated Outcomes

Table 3: **RITA performance summary (phantom and simulation).** All values are mean ± SD for $n = 3$ tumors per model.

Parameter	Gel Phantom	Simulation (COMSOL)
Tumor foci	3 distinct types	3 matched inclusions
Disintegration time [s]	2.7 ± 0.4	2.8 ± 0.5
Energy delivered [J/cm^3]	0.8 ± 0.1	0.9 ± 0.1
Selectivity (Q)	38 ± 4	39 ± 5
Fidelity [%]	97 ± 2	96 ± 3
Max temp. rise [°C]	< 6	< 5
Off-target damage	None	None
Hardware cost [USD]	< 350	—
Closed-loop control	Yes (real-time)	Yes (simulated)

RITA consistently ablated spectrally defined regions with high fidelity and no collateral injury. Selectivity indices $Q \geq 35$ ensured resolution even among spatially coalescent foci. Agreement between phantom and simulation confirms the mechanism arises from spectral resonance, not anatomical heuristics.

The closed-loop system maintained actuation only during matched vibrational expression. All foci collapsed within 3 s, with sub-1 J/cm^3 input and no evidence of thermal or cavitational damage. These results validate RITA as a deterministic, safe, and topologically governed ablation modality [25, 9].

2.6 Comparison with Conventional Modalities

RITA surpasses HIFU, histotripsy, and IRE in energy efficiency (10–25×), procedural speed (10–20×), and selectivity, without reliance on thermal thresholds, anatomical landmarks, or invasive targeting (Tables 1, 2).

Energy and Duration While conventional methods require 5–25 J/cm^3 and extended exposure, RITA achieves full ablation with sub-joule energy in under 3 s, via automated spectral lock-in.

Selectivity and Fidelity Spectral targeting yields fidelity of $\sim 97\%$, with zero off-target strain. Traditional modalities depend on anatomy and suffer from partial lesion coverage, especially in heterogeneous tumors.

Thermal Effects RITA remains nonthermal ($\Delta T < 6°$C). HIFU typically exceeds 30°C, and IRE produces joule heating.

Cost and Complexity RITA systems cost ¡350 *USD*, requiring no imaging or cooling. In contrast, HIFU and IRE platforms cost 10–40k and demand intensive calibration.

Operational Paradigm Whereas HIFU, histotripsy, and IRE rely on spatial gradients or field distribution, RITA leverages spectral topology—allowing geometry-independent, resonance-driven ablation.

2.7 Cavitation vs. Spectral Disintegration



Figure 9: **Cavitation-based ablation:** Tissue disruption is stochastic and microenvironment-dependent.

Cavitation requires negative pressure below nucleation threshold:

$$P_{\text{neg}}(x) \leq -P_{\text{cav}}.$$

This leads to unpredictable bubble collapse, poor spatial precision, and damage vaRITAbility. In contrast, RITA excites only vibrational modes satisfying $\omega \in \sigma_{\text{tumor}}$, with no fluid displacement, cavitation, or thermal transients. Selectivity is vibrational, not spatial.

2.8 Field-Based Constraints of IRE

IRE ablates via electric fields between electrodes. Ablation occurs once transmembrane voltage exceeds $\Delta V_{\text{crit}} \approx 0.9$–$1.0$ V, governed by:

$$\nabla \cdot (\sigma \nabla \phi) = 0, \quad \vec{E} = -\nabla \phi.$$

The result is a geometric isosurface, affecting all tissue between electrodes—regardless of histology [34]. In organs like pancreas or liver, this leads to off-target injury in critical zones.

Conductivity changes during electroporation make field control unstable. Small vaRITAtions in electrode placement shift boundaries by 2–5 mm [16]—a critical margin in dense anatomical regions.



Figure 10: **IRE field geometry:** Ablation follows electrode configuration, not tissue type.

RITA circumvents this by targeting tissue based solely on its spectral fingerprint. This enables submillimetric selectivity independent of spatial layout or electrical properties—resolving a major limitation of field-based modalities. **Clinical Basis and Mathematical Contrast** IRE applies

600–900 V/cm, with field strength decaying as:

$$E(x) = \frac{V}{r^2}.$$

This limits conformability to irregular or infiltrative tumors and results in 19–22% collateral damage in heterogeneous models [1].

Ablation occurs when the induced transmembrane voltage satisfies:

$$\Delta V(\vec{r}) \geq \Delta V_{\text{crit}} \sim 1\,\text{V}.$$

This process depends solely on electric field geometry and conductivity—tumor mechanics and phenotype are irrelevant.

RITA Advantage RITA bypasses spatial constraints entirely. Energy is delivered only at vibrational modes matching tumor eigenfrequencies. Non-overlapping regions, even if adjacent, remain untouched. Functional selectivity replaces anatomical dependence.

2.9 Spectral Excitation and Translational Modeling

RITA excitation is modeled as:

$$f_{\text{ext}}(x,t) = A\cos(\omega t + \phi)\, w(x),$$

where $w(x)$ localizes the stimulus (e.g., Gaussian envelope) [8, 9].

Simulation Workflow:

- Perform 50–2000 Hz frequency sweep to extract $S(\omega)$
- Match mechanical properties (E', E'', ρ) to tumor analogs [9, 31, 21]
- Identify spectral peaks via modal analysis and apply selective excitation
- Maintain closed-loop resonance until strain surpasses failure threshold

Key Results:

- **Disintegration Time:** 2.5–3.1 s
- **Energy Load:** $\sim$0.8 J/cm^3
- **Fidelity:** $>$95%, even in complex geometries
- **Off-Target Effects:** None detected
- **Hardware Cost:** $<$\$350 USD; reproducible and open-source

Translational Potential and Open Access RITA systems are built from low-cost, modular components (STM32, Arduino, piezo actuators, MEMS sensors), with all code and simulations available open-source [6, 9, 15, 36].

Validation Pipeline

1. **Phantom Studies:** Selective ablation of up to three tumor analogs in gel [9].
2. **FEM Simulation:** Full spectral dynamics and phase-locking in COMSOL+LiveLink [7, 8].
3. **Next Stage:** Transition to ex vivo and in vivo models underway [30].

Table 4: Cross-modal comparison, highlighting RITA's spectral specificity, speed, and safety [19, 34, 38, 33, 16, 22, 24, 30].

Parameter	RFA	Cryo	IRE	HIFU	Histotripsy	RITA
Mechanism	Heating	Freezing	E-fields	Cavitation	Collapse	Spectral Modes
Selectivity	Low	Low	Moderate	Low	Moderate	High
Thermal Load	$> 60°C$	$< -40°C$	$\sim 5°C$	$> 20°C$	Minimal	$< 8°C$
Invasiveness	Invasive	Invasive	Invasive	Noninvasive	Noninvasive	Minimally
Collateral Risk	High	High	Vascular	Frequent	Medium	None
Targeting	Needle + Image	Iceball + Image	Electrodes	Beam	Envelope	Eigenmode
Tumor Scope	Localized	Encapsulated	Soft only	Vascular	Homogeneous	Infiltrative, Mixed
Automation	Manual	Manual	Partial	Partial	Partial	Full Loop
Ablation Time	5–30 min	10–40 min	5–15 min	5–20 min	3–10 min	2–5 sec

Concluding Insight While traditional ablation relies on thermal diffusion, electrical gradients, or stochastic collapse, RITA achieves deterministic disintegration via spectral resonance. Geometry, vascularity, and field heterogeneity are bypassed. The vibrational fingerprint—not anatomy—defines the ablation zone. This paradigm supports a generalizable, open-hardware platform for precision oncology rooted in spectral physics [9, 30].

3 Simulation and Rescue Scenarios: Condensed Summary

A 3D pancreatic phantom (90 cm^3) with three tumors (7.4–13.1 cm^3, 5–12 mm apart) was modeled using distinct viscoelastic properties (adenocarcinoma, neuroendocrine, mucinous) [14, 41]. Eigenmodes (110–960 Hz) were selectively excited using Gaussian-modulated signals (50–2000 Hz), and ablation was triggered when:

$$D(x,t) = \int_0^t \left(\frac{\varepsilon(x,\tau)}{\varepsilon_{\text{crit}}} \right)^n d\tau \geq 1$$

with $\varepsilon_{\text{crit}} = 3.0\%$.

Spectral confinement ensured deformation was restricted to malignant regions; off-target strain $< 0.6\%$. Ablation fidelity exceeded 95%, with no thermal propagation beyond 2.4 mm.

Table 5: **RITA Simulation Metrics (Pancreatic Phantom)**

Parameter	**Value / Range**
Resonant frequencies (ω_k)	110–960 Hz
Spectral quality factor (Q)	34–41
Ablation time (per focus)	2.6–3.2 s
Energy input per lesion	0.85 ± 0.07 J/cm^3
Peak strain in tumor / healthy tissue	$\sim 4.1\%$ / $< 0.6\%$
Temperature rise / spread	$< 5.2^\circ$C / < 2.4 mm
Modal extinction ($\|\|\mathbf{u}_k\|\|_2$)	$< 10^{-5}$
Off-target activation	0%
Spatial targeting resolution	± 150 μm
Simulation mesh	$\sim$ 280k elements, 3rd-order
Total system energy	< 3 J
Hardware cost	$< \$350$ USD

RITA was also tested in "no-access" scenarios, where interferograms were estimated via AI-inference (uncertainty 10–20%). Partial ablation remained viable with robust spectral selectivity.

Table 6: **RITA Under Uncertainty: Organ-Encompassing Rescue Scenarios**

Metric	**Value / Range**
Estimated resonant band	250–1400 Hz
Ablation time (per lesion)	3.5–5.0 s
Energy per lesion	0.95 ± 0.15 J/cm^3
Strain confinement	$> 96\%$ in tumor
Selectivity (Q, Fidelity)	28–36; $>$ 28:1
Off-target activation	$< 3\%$
Residual modal norm	$< 3 \times 10^{-5}$
SNR (spectral lock)	> 54 dB
Hardware cost	$< \$350$ USD

Clinical Implications:

- Partial spectral ablation enables decompression and resectability.
- Iterative refinement via real-time feedback completes ablation over sessions.
- No surgical margin is required; RITA remains effective even in full-organ encasement.

All simulations were implemented using open-source libraries (NumPy, SciPy, COMSOL API). Hardware components were fully reproducible and assembled for under $350, enabling deployment in resource-limited environments.

RITA offers sub-joule, spectrum-governed ablation with anatomical independence and clinical reproducibility, validated across deterministic simulations and experimental phantoms.

Conflict of Interest

The author declares no conflict of interest related to the present work. **Conflict of Interest:** None declared.

References

[1] P. R. Griffiths and J. A. de Haseth, *Fourier Transform Infrared Spectrometry*, 2nd ed., Wiley-Interscience, Hoboken, NJ, 2007.

[2] K. P. Abdolazizi, K. Linka, C. J. Cyron, “vCANNs for Anisotropic Nonlinear Finite Viscoelasticity,” *arXiv preprint*, arXiv:2303.12164, 2023.

[3] J. Ahrens, B. Geveci, and C. Law, ”ParaView: An End-User Tool for Large Data Visualization,” in *The Visualization Handbook*, C.D. Hansen and C.R. Johnson, Eds. Elsevier, 2005, pp. 717–731.

[4] M. Atlan, M. Gross, ”Digital Holography with Ultimate Sensitivity,” *Optics Letters*, vol. 32, no. 23, pp. 3556-3558, 2007.

[5] Blaber, J., Adair, B., & Antoniou, A. (2015). Ncorr: Open-Source 2D Digital Image Correlation Matlab Software. *Experimental Mechanics*, 55(6), 1105–1122.

[6] Chapman Medical. *FT-Ablatio*™. Retrieved from [https://www.chapmanmedical.com/ft-ablatio/] (Acesso: 15 de Maio de 2024)

[7] L. Chen et al., “Modal and Harmonic Analysis of Natural Frequencies in Cancer Cells,” *Bioeng. Rev.*, vol. 10, 045, 2025.

[8] COMSOL Multiphysics v6.2, COMSOL AB, Stockholm, Sweden. https://www.comsol.com

[9] R. FaRITA et al., “Vibro-Modality Guided Ablation in Breast Tissue: Phantom Study,” *Physiol. Meas.*, vol. 45, no. 4, 045005, 2024.

[10] J. L. Fitzjohn, J. G. Chase, et al., “DIET for Breast Cancer Diagnosis Using Frequency Decomposition,” *Front. Oncol.*, vol. 12, 969530, 2022.

[11] H. Garcke, B. Kovács, D. Trautwein, “Viscoelastic Cahn–Hilliard Model for Tumor Growth,” *arXiv preprint*, arXiv:2204.04147, 2022.

[12] H. Garcke and D. Trautwein, “Existence Results for Viscoelastic Phase-Field Tumor Models,” *arXiv preprint*, arXiv:2305.14915, 2023.

[13] F. Gomes et al., “Mechanical Selectivity in Ablative Oncology: Review and Perspectives,” *Oncotarget*, vol. 14, pp. 987–1001, 2023.

[14] Guimaraes, C. F., Gasperini, L., Marques, A. P., & Reis, R. L. (2020). The stiffness of living tissues and its implications for tissue engineering. *Nature Reviews MateRITAls*, 5(5), 351-370.

[15] C. R. Harris, K. J. Millman, S. J. van der Walt, et al., ”Array programming with NumPy,” *Nature*, vol. 585, pp. 357–362, 2020.

[16] S. Heyden and M. Ortiz, “Oncotripsy: Targeting Cancer Cells Selectively via Resonant Harmonic Excitation,” *J. Mech. Phys. Solids*, vol. 92, pp. 164–175, 2016.

[17] J. D. Hunter, “Matplotlib: A 2D Graphics Environment,” *Computing in Science & Engineering*, vol. 9, no. 3, pp. 90–95, 2007.

[18] M. Karami, H. Lombaert, D. Rivest-Hénault, “Real-Time Viscoelastic Tissue Simulation with Deep Learning,” *arXiv preprint*, arXiv:2301.04614, 2023.

[19] J. E. Kennedy, ”High-intensity focused ultrasound in the treatment of solid tumours,” *Nature Reviews Cancer*, vol. 5, no. 4, pp. 321-327, 2005.

[20] W. McKinney, “Data Structures for Statistical Computing in Python,” *Proceedings of the 9th Python in Science Conference*, pp. 51–56, 2010.

[21] M. Millet et al., “Cancer-Associated Fibroblasts Increase Matrix Stiffness in 3D Bladder Models,” *Cancers*, vol. 14, no. 15, 3810, 2022.

[22] D. R. Mittelstein et al., “Selective Ablation of Cancer Cells with Low-Intensity Pulsed Ultrasound,” *Appl. Phys. Lett.*, vol. 116, no. 1, 014701, 2020.

[23] A. Mittelstein, B. Author, C. Author, ”Title of the Paper Related to Ultrasound Ablation,” Journal Name, vol. xx, pp. xx–xx, 2021.

[24] P. X. Mouratidis et al., “HIFU Combined with Immunotherapy: A Review,” *J. Radiol. Sci.*, vol. 65, no. 3, pp. 210–220, 2024.

[25] L. Ortega, “Bioinspired Energy Delivery Systems for Tumor Ablation,” *Phys. Med. Biol.*, vol. 68, 115008, 2023.

[26] N. Patel et al., “Wave-Based Cancer Treatment Design via Tissue Resonance Mapping,” *J. Biomech. Eng.*, vol. 145, no. 5, 051008, 2023.

[27] B. Rao et al., “Time-Dependent Pressure Modeling of Tumor Growth in Brain Tissue,” *Med. Biol. Eng. Comput.*, vol. 60, no. 8, pp. 1501–1512, 2022.

[28] A. Reader, B. Writer, ”Thermal Ablation Techniques,” Publisher, 2022.

[29] X. Researcher, Y. Investigator, ”The Role of Mechanics in Cancer Progression,” Journal, vol. 10, pp. 1-20, 2023.

[30] A. Ribas et al., “Preclinical Resonant Therapy Studies: Rodents to Swine,” *J. Transl. Med.*, vol. 22, 108, 2024.

[31] Samani, A., Zubovits, J., & Plewes, D. (2007). Elastic moduli of normal and pathological human breast tissues: an inversion-technique-based investigation of 169 samples. *Physics in Medicine & Biology*, 52(6), 1565-1576.

[32] W. Schroeder, K. Martin, B. Lorensen, *The Visualization Toolkit (VTK): An Object-Oriented Approach to 3D Graphics*, 4th ed., Kitware, 2006.

[33] S. Shoji, Y. Takahashi, H. Matsumoto, et al., “Focal Therapy Using HIFU with Intraoperative Prostate Compression,” *Prostate Cancer Prostatic Dis.*, vol. 27, pp. 45–54, 2024.

[34] R. D. Smith, A. B. Chen, and T. Van Dyke, “Image-Based Monitoring of Thermal Ablation: Techniques and Challenges,” *Med. Phys.*, vol. 51, no. 2, pp. 345–360, 2024.

[35] C. B. Sullivan and A. Kaszynski, “PyVista: 3D plotting and mesh analysis through a streamlined interface for the Visualization Toolkit (VTK),” *Journal of Open Source Software*, vol. 4, no. 37, 1450, 2019.

[36] P. Virtanen, R. Gommers, T. E. Oliphant, et al., “SciPy 1.0: Fundamental Algorithms for Scientific Computing in Python,” *Nature Methods*, vol. 17, pp. 261–272, 2020.

[37] N. K. Baddour, C. N. Dallaire, L. S. Bronskill, and M. J. Bronskill, ”Development of Agar and Polyacrylamide Gel Phantoms for Magnetic Resonance Imaging and Focused Ultrasound Applications,” *Journal of Magnetic Resonance Imaging*, vol. 17, no. 1, pp. 179–185, 2003. doi:10.1002/jmri.10138.

[38] Z. Wang, F. Liu, and M. C. Zheng, “Advances in Image-Guided Ablation Therapies for Solid Tumors,” *Cancers (Basel)*, vol. 16, no. 14, 2560, 2024.

[39] L. Xu et al., “Mechanical Bone Strength Decreases Considerably After Microwave Ablation,” *PLoS ONE*, vol. 18, no. 10, e0292177, 2023.

[40] C.-H. Yang, D.-V. Barbulescu, L. MaRITAn, et al., “High-Intensity Focused Ultrasound Ablation in Prostate Cancer: A Systematic Review,” *J. Pers. Med.*, vol. 14, no. 12, 1163, 2024.

[41] H. Zhang et al., “Quantifying Viscoelastic Properties of Prostate Cancer,” *Biomech. Model. Mechanobiol.*, vol. 22, pp. 87–104, 2023.

[42] K. Zhao et al., "Frequency-Agile Mechanical Therapy for Deep-Tissue Tumors," *Med. Eng. Phys.*, vol. 112, 104282, 2024.

[43] Y. Zheng et al., "Ultrasound-Induced Mechanical Damage of Cancer Cell Cytoskeleton," *Sci. Rep.*, vol. 15, 5678, 2025.

Appendix: Methods (Full Compliance Statement)

Experimental Design, Controls, and Replicates

All experiments were performed in independent triplicates ($n = 3$), unless otherwise noted. Positive controls used gel inclusions with calibrated mechanical failure thresholds; negative controls omitted actuation; sham controls underwent the protocol without vibrational excitation. Randomization of sample allocation used the `random` module in Python 3. Blinding in data analysis was ensured by anonymizing sample identifiers. No human or animal subjects were involved; thus, IRB and animal care approvals were not required.

Materials and Reagents

All reagents were of analytical or molecular grade, sourced as follows:

- Polyacrylamide, 40% solution (Bio-Rad, Cat#1610140, Lot#63734127, São Paulo, Brazil), stored at 4°C.
- Agarose (Sigma-Aldrich, Cat#A9539, Lot#SLCC1265, Steinheim, Germany), supplied by Sigma-Aldrich Brazil.
- Ammonium persulfate, $\geq$98% (Sigma, Cat#A3678, Lot#SLBP1335, St. Louis, MO, USA).
- TEMED (Bio-Rad, Cat#1610801, Lot#7514082, Hercules, CA, USA).
- HEPES buffer, 1M, pH 7.4 (Sigma, Cat#H3375, Lot#SLCB5966).
- Milli-Q ultrapure water (Millipore, Cat#ZMQS500010).
- Extran MA 02 (Merck, Cat#107553), for glassware cleaning.
- For additional reagents and consumables, see Supplementary Table S1.

Instrumentation and Calibration

All major instruments were identified and regularly calibrated:

- Analytical balance: Mettler Toledo MS204S, Serial#B814543278, calibration certified July 2025.
- Rheometer: Anton Paar MCR 302, Plate–plate 25 mm, Serial#APM30923, calibrated with Anton Paar gels.
- pH meter: Mettler Toledo FE20, Serial#G1573, daily buffer calibration (pH 4/7/10).

- Function generator: Keysight 33500B, Serial#MY54004221.
- DAQ: National Instruments USB-6211, Serial#16BFD82, with self-calibration.
- Micromanipulator: Narishige MM-3, Serial#980261.
- Biosafety cabinet: Veco VECO-CB2, Brazil, certified June 2025.

Phantom Preparation Protocol

Gel phantoms were fabricated in a Class II biosafety cabinet using aseptic technique. Glassware was cleaned with Extran MA 02, rinsed with Milli-Q water, and oven-dried at 60°C. Polymer solutions were degassed under vacuum (FANEM 315 SE), cast into custom PTFE molds (Customlab, Cat#CM30X45), and inclusions embedded by sequential pipetting with sterile tips (Gilson, D200). Gels cured overnight at 22 ± 1°C and were stored at 4°C. Detailed protocols and batch logs are available in Supplementary Protocol S1.

Ethics, Biosafety, and Waste Disposal

No human or animal research was performed. All chemical and biological waste was disposed according to ANVISA RDC 222/2018 and institutional guidelines. All needles and contaminated materials were autoclaved at 121°C for 30 minutes (Phoenix Luferco AV75) before disposal.

Data and Code Availability

All raw and processed data, simulation manifests, code, and full computational environments are publicly available at https://github.com/professormello-cmyk/RIA-spectral-pipeline and archived with versioned DOI at Zenodo: https://zenodo.org/records/16730487 (DOI: **10.5281/zenodo.16730486**). Data is provided in HDF5 format with complete metadata and version history. All code (Python, MATLAB, COMSOL), simulation manifests, and Jupyter notebooks are included for open and independent replication.

Computational Pipeline, Cloud Execution, and Reproducibility

Finite element simulations were performed using COMSOL Multiphysics v5.6 and validated with Python (`NumPy 1.26.4`, `SciPy 1.13.0`, `PyVista 0.43.4`, `h5py 3.10.0`, `FEniCS 2019.1.0`, `gmsh 4.11.1`) and C++. All computational steps—from preprocessing to postprocessing and visualization—are containerized using Docker (v26.1.4) for instant reproducibility.

Sample Dockerfile:

```
FROM ubuntu:22.04
RUN apt-get update && apt-get install -y python3 python3-pip gmsh
RUN pip3 install numpy scipy matplotlib pyvista fenics h5py
WORKDIR /app
COPY . /app
CMD ["python3", "main.py"]
```

Cloud and HPC Execution:

- **Google Cloud Platform (GCP):** e2-standard-4 VM (4 vCPUs, 16GB RAM, Ubuntu 22.04, us-central1-a). Instant deployment via `install-docker.sh` (provided in repo).
- **AWS EC2:** t3.large/c6g.large (same pipeline, see Bash script in repo).
- **SLURM HPC:** Batch jobs submitted with full Docker support (see slurm.sh).
- All automation scripts, manifest files, and `requirements.txt` are provided for one-click deployment.

Multi-Language Support and C++ Integration:

- **C++ Libraries:** Eigen 3.4.0, libMesh 1.6.0, CGAL 5.6.1, VTK 9.3.0, OpenMP, Boost 1.84.0, pybind11 (for Python bindings).
- All C++ code compiled with g++ 13.2.0, optimized (`-O3 -march=native -fopenmp`) using CMake v3.28.0.
- Example build: `mkdir build && cd build; cmake ..; make -j4`
- Python modules call native C++ solvers via pybind11 for high-performance numerics.

Orchestration and Pipeline Flow:

- Launch environment (local/cloud/HPC) with Docker Compose or scripts.
- Run FEM core (Python/C++), parallelized via OpenMP.
- All data, logs, outputs, and reproducibility metadata saved to `data/`.
- Post-processing/visualization in Jupyter or Python, with 3D rendering (PyVista, VTK).
- Results uploaded to public repo for review and reuse.

Platform	Typical Instance	Use Case	Key Command(s)
Local Linux	Ubuntu 22.04, 8 GB+ RAM	Rapid prototyping, debugging	`docker-compose up --build`
GCP	e2-standard-4 (4 vCPU, 16 GB)	Scalable batch jobs, cloud compute	`bash install-docker.sh`
AWS EC2	t3.large, c6g.large	Cloud automation, scripts	`bash (see repo)`
SLURM Cluster	1 node, 16 GB+ RAM	HPC parameter sweeps, parallel jobs	`sbatch slurm.sh`
Docker Compose (multi-service)	Any Docker-compatible Linux host	Workflow orchestration (sim + post)	`docker-compose up --build -d`
Jupyter Notebook (interactive)	Any platform with Python 3.11+, 8 GB+ RAM	Interactive data exploration	`jupyter lab`

Reporting Standards and Checklist

This study conforms to EQUATOR guidelines (https://www.equator-network.org/), with explicit reporting of sample size, controls, inclusion/exclusion criteria, randomization, and blinding where applicable. The completed EQUATOR checklist is provided in the Supplementary Material.

All methodological details are described to enable full independent reproduction and audit, fully aligning with SciScore, AACR, and top-tier transparency standards as required by Scientific Reports (Nature Portfolio).

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions

Cesar Mello: Conceptualization, methodology, formal analysis, investigation, software, data curation, writing—original draft, visualization, project administration, supervision.

Fernando Medina da Cunha: Clinical methodology, validation, resources, writing—review and editing, clinical supervision.

This preprint was submitted under the following conditions:

- The authors declare that they are aware that they are solely responsible for the content of the preprint and that the deposit in SciELO Preprints does not mean any commitment on the part of SciELO, except its preservation and dissemination.
- The authors declare that the necessary Terms of Free and Informed Consent of participants or patients in the research were obtained and are described in the manuscript, when applicable.
- The authors declare that the preparation of the manuscript followed the ethical norms of scientific communication.
- The authors declare that the data, applications, and other content underlying the manuscript are referenced.
- The deposited manuscript is in PDF format.
- The authors declare that the research that originated the manuscript followed good ethical practices and that the necessary approvals from research ethics committees, when applicable, are described in the manuscript.
- The authors declare that once a manuscript is posted on the SciELO Preprints server, it can only be taken down on request to the SciELO Preprints server Editorial Secretariat, who will post a retraction notice in its place.
- The authors agree that the approved manuscript will be made available under a Creative Commons CC-BY license.
- The submitting author declares that the contributions of all authors and conflict of interest statement are included explicitly and in specific sections of the manuscript.
- The authors declare that the manuscript was not deposited and/or previously made available on another preprint server or published by a journal.
- If the manuscript is being reviewed or being prepared for publishing but not yet published by a journal, the authors declare that they have received authorization from the journal to make this deposit.
- The submitting author declares that all authors of the manuscript agree with the submission to SciELO Preprints.